Full Press Release Details
INmune Bio, Inc. Announces Lead Drug Candidate
XPro1595 Receives Chemical Drug Name pegipanermin from USAN
LA JOLLA, Calif, June 02, 2021 (GLOBE NEWSWIRE)
-- -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatments
that harness the patient's innate immune system to fight disease, announced today that the United States Adopted Name Council (USAN)
has adopted the name "Pegipanermin" for its lead clinical candidate, XPro1595.
"We are pleased that USAN has approved pegipanermin as
the generic name for XPro1595," stated RJ Tesi, MD, Chief Executive Officer of INmune Bio. "Applying for and receiving a generic
drug name is a necessary step in the drug development process that reflects that a program has matured beyond the experimental stage to
the development stage with a potential path to market. In the near term, we will be evaluating pegipanermin as a potential
treatment for Alzheimer's disease and treatment resistant depression. We look forward to advancing this novel compound into Phase
2 studies in two CNS indications later this year."
INmune reported positive Phase 1b Alzheimer's
data in January 2021 demonstrating that XPro1595 decreased neuroinflammation and neurodegeneration biomarkers in patients with mild
to moderate Alzheimer's. The company is planning to initiate two Phase 2 clinical trials of XPro1595, in Alzheimer's and Treatment
Resistant Depression, in 2021.
About XPro1595 (Pegipanermin)
XPro1595 is a next-generation inhibitor of
tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block
the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane
TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer's and other neurodegenerative
diseases by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve
cognitive function and restore neuronal communication visit this section of the INmune Bio's website.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ:
INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune
Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF,
a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications
(Quellor ), cancer (INB03 ), Alzheimer's and Treatment Resistant Depression (XPro1595), and NASH (LIVNate ). The
Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual
disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide
variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Information about Forward-Looking Statements
Clinical trials are in early stages and there
is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements
contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations
but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 , Quellor , XPro1595,
LIVNate , and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there
cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual
future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the
Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to
continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's
business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors
are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports
on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance
that may arise after the date of this release.
LifeSci Communications